Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2008

View Archived Issues

FMP2.1/AS02A immunogenic in malaria-experienced population

Preclinical profile of Pfizer's novel NOP receptor agonist

EpiCept reports positive results from phase II Neuracept trial of EpiCept NP-1 for DPN

Calibrant enters collaboration with Yale University for ovarian and breast cancer drug targets

FDA approves BioMarck's plans for phase II trial of BIO-11006 for COPD

ArQule receives milestone payment from Kyowa Hakko relating to ARQ-197

Nile Therapeutics initiates dosing in phase Ib clinical study of CD-NP for heart failure

Novo Nordisk pays milestone payment to Neose for factor VIII program for hemophilia A

HE-3235 active in hormone-independent prostate cancer models

FDA advisory committee supports approval of Zyprexa long-acting injection for schizophrenia

Lovastatin safe in children with neurofibromatosis type 1 / News in Context

FDA grants orphan drug designation to ARG-201 for diffuse systemic sclerosis

Spectrum initiates phase I trial for SPI-1620 as an adjunct to cancer chemotherapy

Metabonomic study shows different brain chemical profile in bipolar disorder

Enanta describes new remedial option for HCV infection in a recent patent

New treatment alternative for glaucoma imparted in recent Allergan patent

Novel therapeutic agents for HIV infection disclosed in patent literature

InNexus announces preliminary results from animal study of DXL-625 for NHL

NIAID reports negative results from phase III HPTN-039 clinical study of aciclovir

FDA extends NDA action date for Entereg

Newron acquires U.K. biopharmaceutical Hunter-Fleming

FDA inquiry into Allergan's Botox dose regimen relates to medical not cosmetic uses

VGX Pharmaceuticals files IND for DNA therapy to treat cancer cachexia and anemia

Transdel submits to FDA phase III clinical study proposal for Ketotransdel in acute pain